UNSPSC 51112706: Satraplatin

This classification denotes a platinum compound with the molecular formula C6H13N.2C2H3O2.2Cl. Pt.H3N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8D7B37T28G, chemically known as platinum, bis(acetato-o)amminedichloro(cyclohexanamine)-, (oc-6-43)- but more generally known as satraplatin, which bears US NIH Compound Identifier 123974. European Medicines Agency schedules Satraplatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04333MIG.

UNSPSC 51112706 Satraplatin is a Commodity code representing pharmaceutical products, specifically the chemotherapy agent satraplatin, though recent state and local procurement activity under this code shows limited direct solicitation. The single recent opportunity in the record is the Texas Health and Human Services Commission's Request for Information (RFI) HHS0017013, posted April 3, 2026, which explores vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program rather than soliciting satraplatin procurement directly. State health and human services agencies represent the primary issuing bodies under this code tier, seeking to understand market capacity for direct contracting with pharmaceutical manufacturers outside traditional pharmacy benefit manager, group purchasing organization, and wholesaler channels. The RFI requests vendor experience with negotiated net pricing models, value-based agreements, and fulfillment strategies for self-insured employers and government health plans, indicating state procurement focus on cost management and supply chain optimization in pharmaceutical purchasing rather than product-specific acquisitions tagged at the commodity level.

Activity under this code concentrates in Texas, where the HHS Commission RFI serves as a foundational market-research mechanism to inform future formal procurement strategy before issuing a Request for Proposal with established financial and temporal parameters. The RFI deadline was April 3, 2026, with no award value, budget range, set-asides, or implementation timelines specified at the information-gathering stage. Given the exploratory nature of the single recent opportunity and the absence of traditional competitive solicitations naming satraplatin directly, this code shows minimal current procurement velocity. Business development professionals should monitor for subsequent formal RFPs from Texas HHS or other state pharmacy benefit programs that may follow this market-research phase, but current activity under the Satraplatin commodity code itself remains sparse relative to broader pharmaceutical procurement at the family or class level.